ATE343381T1 - Verfahren zum auffinden von arzneimitteln zur behandlung von alzheimer-krankheit - Google Patents

Verfahren zum auffinden von arzneimitteln zur behandlung von alzheimer-krankheit

Info

Publication number
ATE343381T1
ATE343381T1 AT96928824T AT96928824T ATE343381T1 AT E343381 T1 ATE343381 T1 AT E343381T1 AT 96928824 T AT96928824 T AT 96928824T AT 96928824 T AT96928824 T AT 96928824T AT E343381 T1 ATE343381 T1 AT E343381T1
Authority
AT
Austria
Prior art keywords
mammal
fatty acid
treatment
alzheimer
protein
Prior art date
Application number
AT96928824T
Other languages
English (en)
Inventor
David M Wilson
Lester I Binder
Original Assignee
Univ Alabama Birmingham Res Fo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alabama Birmingham Res Fo filed Critical Univ Alabama Birmingham Res Fo
Application granted granted Critical
Publication of ATE343381T1 publication Critical patent/ATE343381T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT96928824T 1995-08-08 1996-08-07 Verfahren zum auffinden von arzneimitteln zur behandlung von alzheimer-krankheit ATE343381T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202395P 1995-08-08 1995-08-08

Publications (1)

Publication Number Publication Date
ATE343381T1 true ATE343381T1 (de) 2006-11-15

Family

ID=21698903

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96928824T ATE343381T1 (de) 1995-08-08 1996-08-07 Verfahren zum auffinden von arzneimitteln zur behandlung von alzheimer-krankheit

Country Status (7)

Country Link
EP (1) EP0912086B1 (de)
JP (1) JP4135810B2 (de)
AT (1) ATE343381T1 (de)
AU (1) AU718462B2 (de)
CA (1) CA2225647A1 (de)
DE (1) DE69636659T2 (de)
WO (1) WO1997005780A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297998C (fr) 2000-02-03 2010-04-27 Gaston Naessens Solution aqueuse utilisable pour le traitement de maladies degeneratives ou autoimmunes et comme agent immunomodulateur
WO2002010770A2 (en) * 2000-07-31 2002-02-07 Neuronautics, Inc. Improved methods for identifying reagents which inhibit tau polymerization
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
KR101095630B1 (ko) * 2009-06-17 2011-12-19 주식회사 이노파마스크린 베타 아밀로이드 펩타이드와 ｖｅｇｆ의 상호작용을 억제하는 물질을 탐색 방법 및 그에 의해서 탐색된 저해제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0386822A (ja) * 1989-08-30 1991-04-11 Yoshinori Asakawa 神経細胞変性修復剤
JPH07149633A (ja) * 1993-11-26 1995-06-13 Sagami Chem Res Center 神経成長因子産生促進剤
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
US5541208A (en) * 1994-01-24 1996-07-30 Merck & Co., Inc. Indole diterpene alkaloid compounds

Also Published As

Publication number Publication date
DE69636659D1 (de) 2006-12-07
JP2000502043A (ja) 2000-02-22
EP0912086B1 (de) 2006-10-25
EP0912086A4 (de) 2002-04-17
DE69636659T2 (de) 2007-02-01
WO1997005780A1 (en) 1997-02-20
EP0912086A1 (de) 1999-05-06
AU718462B2 (en) 2000-04-13
AU6843896A (en) 1997-03-05
CA2225647A1 (en) 1997-02-20
JP4135810B2 (ja) 2008-08-20

Similar Documents

Publication Publication Date Title
DE69125523D1 (de) Verwendung eines Modulators der Proteinphosphorylierung zur Behandlung der Amyloidosis in Zusammenhang mit der Alzheimerschen Krankheit
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
KR960704839A (ko) β-아밀로이드 단백질 생성 억제제(Inhibitors of β-amyloid protein production)
ATE369379T1 (de) Peptide und auf ihnen basierende pharmazeutische zusammensetzungen zur behandlung von störungen und krankheiten die mit der abnormalen proteinfaltung in amyloiden oder amyloid- ähnlichen ablagerungen zusammenhängen
ATE218336T1 (de) Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
EP0735870A4 (de) Verwendung von phospholipase-a2-inhibitoren zur behandlung der alzheimer-krankheit
DE69428130D1 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
MY121036A (en) Piperazinyl-heterocyclic compounds in the treatment of dementia.
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE178487T1 (de) Verwendung von 2-amino-4-(4-fluorbenzylamino)-1- ethoxycarbonylaminobenzen zur prophylaxe und behandlung der folgen der akuten und chronischen zerebralen minderdurchblutung sowie neurodegenerativer erkrankungen
ATE110958T1 (de) Verwendung von sertralin zur behandlung verfrühter ejakulation.
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69121561D1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69433309D1 (de) Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase
ATE245427T1 (de) Neue verwendung von phospholipiden tierischen ursprungs in der therapie und/oder schonkost
JPH02250895A (ja) 神経調節ペプチド
ATE179888T1 (de) Ophthalmische zubereitung zur behandlung oder prävention von trockenem auge und krankheiten, die dadurch verursacht werden, enthaltend 12- sulfodehydroabietsäure
ATE526981T1 (de) Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
DE69636659D1 (de) Verfahren zum auffinden von arzneimitteln zur behandlung von alzheimer-krankheit
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties